TALTZ (Ixekizumab)
TALTZ Rx

Generic Name and Formulations:

Ixekizumab 80mg/mL; soln for SC inj; preservative-free.

Company:

Lilly, Eli and Company
Indications for TALTZ:

Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Adult:

Rotate inj site (eg, upper arms, thighs, or any quadrant of abdomen). ≥18yrs: 160mg (given as two 80mg SC injections) at Week 0, then 80mg at Weeks 2, 4, 6, 8, 10, and 12, then 80mg every 4 weeks.

Children:

<18yrs: not eva luated.

Warnings/Precautions:

Increased risk of infections. If a serious infection develops, monitor closely and discontinue until resolves. eva luate for TB infection and treat latent TB prior to initiating; monitor for active TB during and after therapy. Active TB infection: do not start. History of latent or active TB without confirmed adequate course of treatment: consider anti-TB therapy prior to initiation. Monitor for inflammatory bowel disease. Discontinue immediately and treat if a serious hypersensitivity reaction occurs. Complete all age appropriate immunizations based on current guidelines prior to initiating. Pregnancy. Nursing mothers.

Interactions:

Avoid concomitant live vaccines. Monitor CYP450 substrates with narrow therapeutic index (eg, warfarin, cyclosporine); consider dose adjustment of these substrates.

Pharmacological Class:

Interleukin-17A antagonist.

Adverse Reactions:

Inj site reactions, upper respiratory tract infections, nausea, tinea infections.

Generic Availability:

NO

How Supplied:

Single-use prefilled autoinjector—1, 2, 3; Single-use prefilled syringe—1, 2, 3